Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452563 | 0.90 | CNR2 (0.84) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5078904 | 0.89 | CNR2 (1.00) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5451173 | 0.88 | CNR2 (0.77) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5459893 | 0.87 | CNR2 (0.80) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5450303 | 0.87 | CNR2 (0.80) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5459860 | 0.87 | CNR2 (0.80) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5445348 | 0.86 | CNR2 (0.79) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5450317 | 0.86 | CNR2 (0.79) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5454265 | 0.86 | CNR2 (0.84) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5082993 | 0.86 | CNR2 (0.78) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562907-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | claimed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1562907-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129367-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP1A2 793/4885CYP2C9 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.